[{"id":"ddd7f583-bad9-403a-9835-38c48d3a337c","acronym":"DARTS","url":"https://clinicaltrials.gov/study/NCT07027436","created_at":"2025-06-21T13:17:48.762Z","updated_at":"2025-06-21T13:17:48.762Z","phase":"Phase 3","brief_title":"Radiation Therapy Followed by Durvalumab (MEDI4736) and Tremelimumab And Surgery Versus Radiation Therapy Followed by Surgery for Resectable Hepatocellular Carcinoma.","source_id_and_acronym":"NCT07027436 - DARTS","lead_sponsor":"Hamilton Health Sciences Corporation","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/07/2025","start_date":" 07/07/2025","primary_txt":" Primary completion: 10/12/2027","primary_completion_date":" 10/12/2027","study_txt":" Completion: 10/10/2028","study_completion_date":" 10/10/2028","last_update_posted":"2025-06-18"},{"id":"2304e211-cb24-49e4-804c-c1f372c07411","acronym":"ARTEMIDE-HCC01","url":"https://clinicaltrials.gov/study/NCT06921785","created_at":"2025-06-07T14:44:45.235Z","updated_at":"2025-06-07T14:44:45.235Z","phase":"Phase 3","brief_title":"Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma","source_id_and_acronym":"NCT06921785 - ARTEMIDE-HCC01","lead_sponsor":"AstraZeneca","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • Imjudo (tremelimumab-actl) • rilvegostomig (AZD2936)"],"overall_status":"Recruiting","enrollment":" Enrollment 1220","initiation":"Initiation: 05/06/2025","start_date":" 05/06/2025","primary_txt":" Primary completion: 03/16/2029","primary_completion_date":" 03/16/2029","study_txt":" Completion: 03/15/2030","study_completion_date":" 03/15/2030","last_update_posted":"2025-05-31"},{"id":"65d9c2cb-0676-43e5-831c-bcc76a373ee1","acronym":"RESOLVE","url":"https://clinicaltrials.gov/study/NCT05154994","created_at":"2021-12-13T14:12:40.514Z","updated_at":"2025-02-25T12:38:04.917Z","phase":"Phase 1","brief_title":"Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in ARID1A Mutated Cancer Focus on Urothelial Carcinoma","source_id_and_acronym":"NCT05154994 - RESOLVE","lead_sponsor":"University of Utah","biomarkers":" ARID1A","pipe":"","alterations":" ","tags":["ARID1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • Beleodaq (belinostat)"],"overall_status":"Suspended","enrollment":" Enrollment 9","initiation":"Initiation: 01/14/2022","start_date":" 01/14/2022","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 11/30/2026","study_completion_date":" 11/30/2026","last_update_posted":"2025-02-24"},{"id":"0a44475b-ada6-49fd-a78d-da7cabf4adaa","acronym":"","url":"https://clinicaltrials.gov/study/NCT02879162","created_at":"2021-01-18T14:08:03.022Z","updated_at":"2025-02-25T14:14:51.028Z","phase":"Phase 2","brief_title":"Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours","source_id_and_acronym":"NCT02879162","lead_sponsor":"Canadian Cancer Trials Group","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)"],"overall_status":"Completed","enrollment":" Enrollment 140","initiation":"Initiation: 12/14/2016","start_date":" 12/14/2016","primary_txt":" Primary completion: 06/20/2021","primary_completion_date":" 06/20/2021","study_txt":" Completion: 01/29/2025","study_completion_date":" 01/29/2025","last_update_posted":"2025-02-17"},{"id":"64db0bf5-eaaf-49e9-a532-d5f1928d23e7","acronym":"","url":"https://clinicaltrials.gov/study/NCT02537418","created_at":"2021-01-18T12:16:25.434Z","updated_at":"2025-02-25T14:06:52.583Z","phase":"Phase 1","brief_title":"Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens","source_id_and_acronym":"NCT02537418","lead_sponsor":"Canadian Cancer Trials Group","biomarkers":" PD-L1 • PD-1 • CTLA4","pipe":"","alterations":" ","tags":["PD-L1 • PD-1 • CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 153","initiation":"Initiation: 10/16/2015","start_date":" 10/16/2015","primary_txt":" Primary completion: 07/20/2018","primary_completion_date":" 07/20/2018","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-17"},{"id":"73c07069-865b-4afb-8b05-dfbb1671005a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04005690","created_at":"2021-01-29T07:19:28.601Z","updated_at":"2025-02-25T15:11:13.905Z","phase":"Phase 1","brief_title":"Targeted Pathway Inhibition in Patients With Pancreatic Cancer","source_id_and_acronym":"NCT04005690","lead_sponsor":"OHSU Knight Cancer Institute","biomarkers":" UGT1A1 • CD4","pipe":" | ","alterations":" UGT1A1*1*1","tags":["UGT1A1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Cotellic (cobimetinib) • Imjudo (tremelimumab-actl) • onvansertib (PCM-075) • azenosertib (ZN-c3) • saruparib (AZD5305) • temuterkib (LY3214996)"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 08/01/2019","start_date":" 08/01/2019","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 02/01/2028","study_completion_date":" 02/01/2028","last_update_posted":"2025-02-13"},{"id":"56a60848-4dfa-45d9-a49c-7194c5f7a955","acronym":"","url":"https://clinicaltrials.gov/study/NCT06564623","created_at":"2025-02-25T15:09:15.826Z","updated_at":"2025-02-25T15:09:15.826Z","phase":"Phase 1","brief_title":"Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)","source_id_and_acronym":"NCT06564623","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" CD8 • CD4","pipe":"","alterations":" ","tags":["CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • Hiltonol (poly-ICLC)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 03/01/2025","start_date":" 03/01/2025","primary_txt":" Primary completion: 03/01/2029","primary_completion_date":" 03/01/2029","study_txt":" Completion: 03/01/2029","study_completion_date":" 03/01/2029","last_update_posted":"2025-02-12"},{"id":"3fd4e005-f66e-41a9-982d-62459a2e84ea","acronym":"NCI-2018-01581","url":"https://clinicaltrials.gov/study/NCT03606967","created_at":"2021-01-18T17:43:57.034Z","updated_at":"2025-02-25T16:37:09.345Z","phase":"Phase 2","brief_title":"Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer","source_id_and_acronym":"NCT03606967 - NCI-2018-01581","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • PD-L1 • ER • PGR • CD4","pipe":" | ","alterations":" PD-L1 expression • HER-2 negative • PD-L1 negative","tags":["HER-2 • PD-L1 • ER • PGR • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 negative • PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Imfinzi (durvalumab) • gemcitabine • albumin-bound paclitaxel • Imjudo (tremelimumab-actl) • Trodelvy (sacituzumab govitecan-hziy) • Hiltonol (poly-ICLC) • liposomal gemcitabine (FF-10832)"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 04/13/2021","start_date":" 04/13/2021","primary_txt":" Primary completion: 11/30/2025","primary_completion_date":" 11/30/2025","study_txt":" Completion: 11/30/2025","study_completion_date":" 11/30/2025","last_update_posted":"2025-02-07"},{"id":"2aac339a-fbd4-48aa-9c04-5e7a6adc7234","acronym":"NCI-MATCH","url":"https://clinicaltrials.gov/study/NCT02465060","created_at":"2021-01-17T17:15:30.769Z","updated_at":"2025-02-25T16:36:36.993Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","source_id_and_acronym":"NCT02465060 - NCI-MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["MSI • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Pertuvia (pertuzumab biosimilar) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6452","initiation":"Initiation: 08/17/2015","start_date":" 08/17/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"5e786cab-df5f-4999-86d9-a6e366a81e36","acronym":"","url":"https://clinicaltrials.gov/study/NCT04499053","created_at":"2021-01-18T21:33:13.928Z","updated_at":"2025-02-25T14:59:17.644Z","phase":"Phase 2","brief_title":"Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer","source_id_and_acronym":"NCT04499053","lead_sponsor":"Georgetown University","biomarkers":" CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 12/09/2020","start_date":" 12/09/2020","primary_txt":" Primary completion: 02/01/2027","primary_completion_date":" 02/01/2027","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2025-02-06"},{"id":"c13367c4-1914-4e69-b5ef-4a4c4565814b","acronym":"DANUBE ","url":"https://clinicaltrials.gov/study/NCT02516241","created_at":"2021-01-17T17:19:50.756Z","updated_at":"2025-02-25T16:36:38.272Z","phase":"Phase 3","brief_title":"Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer","source_id_and_acronym":"NCT02516241 - DANUBE ","lead_sponsor":"AstraZeneca","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 underexpression • PD-L1 negative • PD-L1-L","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 underexpression • PD-L1 negative • PD-L1-L"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • Imfinzi (durvalumab) • gemcitabine • Imjudo (tremelimumab-actl)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1126","initiation":"Initiation: 11/02/2015","start_date":" 11/02/2015","primary_txt":" Primary completion: 01/27/2020","primary_completion_date":" 01/27/2020","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"ef70bd40-bf79-48c4-9e4c-bf5799b604fe","acronym":"","url":"https://clinicaltrials.gov/study/NCT04605731","created_at":"2021-01-19T20:31:23.461Z","updated_at":"2025-02-25T16:45:12.247Z","phase":"Phase 1","brief_title":"Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer","source_id_and_acronym":"NCT04605731","lead_sponsor":"City of Hope Medical Center","biomarkers":" PD-L1 • TMB","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • SIR-Spheres (yttrium-90 microspheres)"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 08/03/2021","start_date":" 08/03/2021","primary_txt":" Primary completion: 08/25/2025","primary_completion_date":" 08/25/2025","study_txt":" Completion: 08/25/2025","study_completion_date":" 08/25/2025","last_update_posted":"2025-02-06"},{"id":"d8999917-3c0d-4b22-aa4a-6a2e1a2de773","acronym":"TRITON","url":"https://clinicaltrials.gov/study/NCT06008093","created_at":"2023-08-23T15:11:10.888Z","updated_at":"2025-02-25T16:55:15.589Z","phase":"Phase 3","brief_title":"A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients","source_id_and_acronym":"NCT06008093 - TRITON","lead_sponsor":"AstraZeneca","biomarkers":" EGFR • KRAS • ALK • STK11 • KEAP1","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • STK11 mutation • ALK fusion • KEAP1 mutation","tags":["EGFR • KRAS • ALK • STK11 • KEAP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • STK11 mutation • ALK fusion • KEAP1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • pemetrexed"],"overall_status":"Recruiting","enrollment":" Enrollment 280","initiation":"Initiation: 04/04/2024","start_date":" 04/04/2024","primary_txt":" Primary completion: 08/17/2027","primary_completion_date":" 08/17/2027","study_txt":" Completion: 03/20/2031","study_completion_date":" 03/20/2031","last_update_posted":"2025-02-04"},{"id":"074f4f72-e179-49af-b9d4-a6b1faee4ca3","acronym":"NRG-GY021","url":"https://clinicaltrials.gov/study/NCT04034927","created_at":"2021-01-18T19:48:04.192Z","updated_at":"2025-02-25T17:00:08.274Z","phase":"Phase 2","brief_title":"Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer","source_id_and_acronym":"NCT04034927 - NRG-GY021","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRCA1 • BRCA2 • BRCA • MUC16","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["BRCA1 • BRCA2 • BRCA • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imjudo (tremelimumab-actl)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 61","initiation":"Initiation: 12/04/2019","start_date":" 12/04/2019","primary_txt":" Primary completion: 07/31/2021","primary_completion_date":" 07/31/2021","study_txt":" Completion: 09/18/2025","study_completion_date":" 09/18/2025","last_update_posted":"2025-02-03"},{"id":"3cde0dfa-68ac-433c-a4ef-75c666c0b155","acronym":"","url":"https://clinicaltrials.gov/study/NCT02888743","created_at":"2021-01-18T14:10:37.843Z","updated_at":"2025-02-25T16:59:14.488Z","phase":"Phase 2","brief_title":"Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer","source_id_and_acronym":"NCT02888743","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ROS1 • MSH6","pipe":" | ","alterations":" PD-L1 expression","tags":["ROS1 • MSH6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 08/14/2017","start_date":" 08/14/2017","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 01/02/2026","study_completion_date":" 01/02/2026","last_update_posted":"2025-02-03"},{"id":"26935637-e7d9-4d4d-a316-807acde84949","acronym":"ADAPT-BLADDER","url":"https://clinicaltrials.gov/study/NCT03317158","created_at":"2021-01-18T16:22:53.823Z","updated_at":"2025-02-25T14:58:27.599Z","phase":"Phase 1/2","brief_title":"Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder","source_id_and_acronym":"NCT03317158 - ADAPT-BLADDER","lead_sponsor":"Noah Hahn, M.D.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • gemcitabine • docetaxel • Imjudo (tremelimumab-actl)"],"overall_status":"Recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 11/21/2017","start_date":" 11/21/2017","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-01-30"},{"id":"aba33b5e-2046-4e2a-9fb8-ed489862ca5d","acronym":"NAUTIC","url":"https://clinicaltrials.gov/study/NCT06494540","created_at":"2025-02-25T17:53:16.413Z","updated_at":"2025-02-25T17:53:16.413Z","phase":"","brief_title":"NIS to Examine the Effectiveness of TDC in Patients With Metastatic Non-squamous NSCLC and High-risk Genetic Alterations","source_id_and_acronym":"NCT06494540 - NAUTIC","lead_sponsor":"AstraZeneca","biomarkers":" KRAS • STK11","pipe":" | ","alterations":" KRAS mutation • STK11 mutation","tags":["KRAS • STK11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • STK11 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)"],"overall_status":"Recruiting","enrollment":" Enrollment 600","initiation":"Initiation: 06/28/2024","start_date":" 06/28/2024","primary_txt":" Primary completion: 06/30/2028","primary_completion_date":" 06/30/2028","study_txt":" Completion: 06/30/2028","study_completion_date":" 06/30/2028","last_update_posted":"2025-01-29"},{"id":"64fbfa8e-e3d5-4527-8e70-e669cf683ef4","acronym":"MOVIE","url":"https://clinicaltrials.gov/study/NCT03518606","created_at":"2021-01-18T17:19:19.354Z","updated_at":"2025-02-25T15:07:35.561Z","phase":"Phase 1/2","brief_title":"Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours","source_id_and_acronym":"NCT03518606 - MOVIE","lead_sponsor":"UNICANCER","biomarkers":" TMB","pipe":"","alterations":" ","tags":["TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • vinorelbine tartrate • Navelbine oral (vinorelbine tartrate oral)"],"overall_status":"Completed","enrollment":" Enrollment 126","initiation":"Initiation: 06/20/2018","start_date":" 06/20/2018","primary_txt":" Primary completion: 04/01/2022","primary_completion_date":" 04/01/2022","study_txt":" Completion: 12/19/2024","study_completion_date":" 12/19/2024","last_update_posted":"2025-01-15"},{"id":"1eead00e-edcb-481b-9a08-390ddb32d124","acronym":"CAMILLA","url":"https://clinicaltrials.gov/study/NCT03539822","created_at":"2021-10-27T20:54:20.716Z","updated_at":"2025-02-25T15:07:39.664Z","phase":"Phase 1/2","brief_title":"Cabozantinib Plus Durvalumab with or Without Tremelimumab in Patients with Gastroesophageal Cancer and Other Gastrointestinal Malignancies","source_id_and_acronym":"NCT03539822 - CAMILLA","lead_sponsor":"Anwaar Saeed","biomarkers":" MSI","pipe":" | ","alterations":" RAS wild-type","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Cabometyx (cabozantinib tablet) • Imjudo (tremelimumab-actl)"],"overall_status":"Recruiting","enrollment":" Enrollment 117","initiation":"Initiation: 10/22/2018","start_date":" 10/22/2018","primary_txt":" Primary completion: 01/31/2027","primary_completion_date":" 01/31/2027","study_txt":" Completion: 01/31/2028","study_completion_date":" 01/31/2028","last_update_posted":"2025-01-14"},{"id":"db3994c6-3749-4a13-acb1-99aa40802cdb","acronym":"CORAL-Lung","url":"https://clinicaltrials.gov/study/NCT05000710","created_at":"2021-08-11T14:55:34.487Z","updated_at":"2025-02-25T15:00:02.742Z","phase":"Phase 2","brief_title":"Concomitant Radiotherapy, Tremelimumab \u0026 Durvalumab for Advanced NSCLC Patients Progressing on First-line Immunotherapy","source_id_and_acronym":"NCT05000710 - CORAL-Lung","lead_sponsor":"Sheba Medical Center","biomarkers":" EGFR • ALK • ROS1","pipe":" | ","alterations":" EGFR mutation • ALK rearrangement • ALK translocation","tags":["EGFR • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK rearrangement • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 12/09/2021","start_date":" 12/09/2021","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-12-05"},{"id":"063a0064-5caa-408a-8c70-d7f6a82b7af1","acronym":"","url":"https://clinicaltrials.gov/study/NCT02953457","created_at":"2021-01-18T14:30:22.179Z","updated_at":"2025-02-25T15:07:19.264Z","phase":"Phase 2","brief_title":"Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation","source_id_and_acronym":"NCT02953457","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 06/29/2017","start_date":" 06/29/2017","primary_txt":" Primary completion: 09/15/2021","primary_completion_date":" 09/15/2021","study_txt":" Completion: 08/15/2024","study_completion_date":" 08/15/2024","last_update_posted":"2024-11-19"},{"id":"12b5c747-ed51-4685-a2bb-fc3b4832f8ea","acronym":"CALYPSO","url":"https://clinicaltrials.gov/study/NCT02819596","created_at":"2021-01-18T13:49:36.169Z","updated_at":"2025-02-25T15:07:06.837Z","phase":"Phase 2","brief_title":"MEDI4736 Combinations in Metastatic Renal Cell Carcinoma","source_id_and_acronym":"NCT02819596 - CALYPSO","lead_sponsor":"Queen Mary University of London","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • Orpathys (savolitinib)"],"overall_status":"Completed","enrollment":" Enrollment 69","initiation":"Initiation: 05/03/2016","start_date":" 05/03/2016","primary_txt":" Primary completion: 07/17/2024","primary_completion_date":" 07/17/2024","study_txt":" Completion: 07/17/2024","study_completion_date":" 07/17/2024","last_update_posted":"2024-11-04"},{"id":"b7163c5c-0370-418e-8711-fbb409699d7b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02962063","created_at":"2021-01-18T14:33:31.039Z","updated_at":"2025-02-25T15:07:20.200Z","phase":"Phase 1/2","brief_title":"Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer","source_id_and_acronym":"NCT02962063","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Imfinzi (durvalumab) • paclitaxel • Imjudo (tremelimumab-actl)"],"overall_status":"Recruiting","enrollment":" Enrollment 79","initiation":"Initiation: 11/01/2016","start_date":" 11/01/2016","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2024-10-16"},{"id":"160aec43-4b7c-4559-89ac-e0a70c118b80","acronym":"","url":"https://clinicaltrials.gov/study/NCT04430452","created_at":"2021-01-18T21:20:12.960Z","updated_at":"2025-02-25T14:59:10.463Z","phase":"Phase 2","brief_title":"Hypofractionated Radiotherapy Followed by Durvalumab With or Without Tremelimumab for Liver Cancer After Progression on PD-1 Inhibition","source_id_and_acronym":"NCT04430452","lead_sponsor":"Mary Feng, MD","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)"],"overall_status":"Recruiting","enrollment":" Enrollment 21","initiation":"Initiation: 02/04/2022","start_date":" 02/04/2022","primary_txt":" Primary completion: 02/28/2027","primary_completion_date":" 02/28/2027","study_txt":" Completion: 02/28/2027","study_completion_date":" 02/28/2027","last_update_posted":"2024-09-19"}]